Enforcement Report - Week of February 7, 2024
Azurity Pharmaceuticals is recalling one batch of Zenzedi 30mg tablets from U.S. shelves after it received a report from a pharmacist in Nebraska who opened a bottle of the narcolepsy treatment and instead found carbinoxamine maleate, an antihistamine drug.
Azurity Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Zenzedi® (dextroamphetamine sulfate tablets, USP) 30 mg Due to a Mislabeled Package During Manufacturing
Enforcement Report - Week of January 10, 2024
Enforcement Report - Week of April 12, 2023
MIAMI, Sept. 7, 2022 /PRNewswire/ -- Brand Institute is proud to announce its work with Azurity Pharmaceuticals (formerly CutisPharma) in developing the brand name KONVOMEP™, which was approved by the FDA on August 30, 2022.
Massachusetts-based Azurity Pharmaceuticals has been doing well this year in getting its products past FDA approval, and the company is looking to continue that trend Friday.
The company plans to make Konvomep available commercially in the US by the first quarter of next year.
Azurity Pharmaceuticals, Inc., a private pharmaceutical company focused on developing innovative products to serve the specific needs of overlooked...